Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) has announced that Torsten Malmström, PhD, has been appointed director of chemistry, manufacturing, and controls (CMC) and joins the company’s management team.
Dr. Malmström brings more than 20 years of experience from the pharmaceutical industry, with a strong focus on CMC, technical operations, and global supply chains. He holds a PhD in chemistry from Lund University and has held senior positions at leading pharmaceutical and biotech companies, including director pharmaceutical development at Zealand Pharma, director development at PolyPeptide Laboratories, and managerial roles at AstraZeneca.
In a statement, Mats Hansen, CEO of Spago, commented, “Torsten’s broad and deep CMC experience, combined with his proven leadership at both executive and operational levels, will be a significant asset as we advance Tumorad towards late-stage clinical development and enhance the program’s attractiveness for future partnerships and commercialization. As the ongoing Tumorad-01 study continues to progress according to plan, strengthening our CMC and supply capabilities is a key part of our preparations for the next clinical development steps and future commercialization. Torsten’s appointment is an important step in that direction.”
